Catalog No.
Product Name
Application
Product Information
Citations
-
Protein Ligand
VH032-C7-COOH is a functionalized ligand targeting the von-Hippel-Lindau (VHL) protein, primarily utilized in PROTAC (Proteolysis Targeting Chimera) research and development. This compound features an E3 ligase ligand along with an alkyl linker terminating in an amine group, facilitating the conjugation of target protein ligands. VH032-C7-COOH supports studies in targeted protein degradation, making it a valuable tool for advancing therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide 4'-alkylC4-acid is an E3 ligase ligand-linker conjugate that incorporates a cereblon ligand, an alkylC4 chain, and a terminal acid. This compound facilitates the synthesis of PROTACs (proteolysis-targeting chimeras) by coupling with targeted protein ligands, enhancing the development of novel protein degradation strategies. Its biochemical properties make it a valuable tool for research in targeted therapeutics and protein modulation studies. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C4-NH2 hydrochloride is a potent E3 ligase ligand-linker conjugate featuring the Pomalidomide-derived cereblon ligand. This compound is designed for use in PROTAC (PROteolysis TArgeting Chimeras) technology, facilitating targeted protein degradation. Its unique structure enables effective modulation of protein levels within cells, making it a valuable tool for chemical biology and therapeutic research applications. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-CO-C2-acid is a functionalized von-Hippel-Lindau (VHL) protein ligand designed for use in E3 ligase ligand-linker conjugates. This compound enables the development of proteolysis-targeting chimeras (PROTACs) by facilitating the conjugation of target protein ligands. Its application enhances the targeted degradation of specific proteins, making it a valuable tool in the field of targeted protein modulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG2-acetic acid is an E3 ligase ligand-linker conjugate designed for use in PROTAC synthesis. This compound facilitates the targeted degradation of specific proteins through the recruitment of E3 ligases, promoting the ubiquitination and subsequent proteasomal degradation of the desired targets. Its innovative structure supports advancements in the development of targeted protein degradation therapies and various cellular research applications. -
E3 Ubiquitin Ligase Ligand-Linker Conjugate
Thalidomide-O-C3-azide is a modified form of the cereblon (CRBN) inhibitor, Thalidomide, featuring an azide group that enables efficient insertion into click chemistry reactions. This compound undergoes copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, making it a valuable tool for the synthesis of E3 ubiquitin ligase ligand-linker conjugates. Thalidomide-O-C3-azide is primarily utilized in the development of PROTACs, facilitating targeted protein degradation studies and advancing research in cellular signaling and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C5-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate that features a VH032-derived VHL ligand coupled with a linker designed for estrogen-related receptor α (ERRα) PROTAC degradation. This compound facilitates targeted protein degradation through specific ubiquitination of ERRα, making it a valuable tool for research applications involving synthetic biology and therapeutic interventions in hormone-related pathways. Its design enhances the efficiency of targeted protein degradation processes, providing researchers with a potent means of modulating protein levels in cellular systems. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C3-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. This compound integrates the cereblon ligand derived from pomalidomide, facilitating targeted protein degradation. Its key applications include studying ubiquitin-proteasome pathways and developing targeted therapeutics for various diseases. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C3-NH2 is an E3 ligase ligand-linker conjugate that incorporates the Lenalidomide-based cereblon (CRBN) ligand. This compound is designed for use in the synthesis of PROTAC BET degrader-2. It enables targeted protein degradation through modulation of E3 ligase activity, making it a valuable tool in research involving protein homeostasis and degradation pathways. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amido-C1-Br is an E3 ligase ligand-linker conjugate that utilizes the cereblon ligand from Pomalidomide, designed for targeted protein degradation applications. This compound serves as a key component in the development of B-Raf PROTACs, specifically aiding in the construction of PROTAC B-Raf degrader 1, which exhibits notable anti-cancer activity. Researchers can leverage this conjugate to explore novel therapeutic strategies for malignancies driven by B-Raf mutations. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-PEG5-Boc is an E3 ligase ligand-linker conjugate designed for targeted protein degradation. This compound combines the (S,R,S)-AHPC variant of the VHL ligand with a polyethylene glycol (PEG) linker to facilitate the efficient ubiquitination of Cdc20. Its primary application lies in the development of targeted therapeutic strategies aimed at modulating protein levels within cellular systems. This compound is ideal for use in drug discovery research focusing on E3 ligase-mediated degradation. -
E3 ligase ligand-Linker Conjugate
(S,R,S)-AHPC-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate designed for use in PROTAC technology. It features the (S,R,S)-AHPC-based VHL ligand along with a three-unit PEG linker that facilitates the targeted degradation of proteins. This compound is essential for studying E3 ligase activity and its applications in targeted protein modulation research. -
E3 Ligase Ligand-Linker Conjugates
Lenalidomide-propargyl-C2-amido-Ph-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring a cereblon (CRBN) ligand. This compound facilitates the design of PROTACs, such as MD-224, enabling targeted protein degradation through the modulation of ubiquitin-proteasome pathways. Additionally, it serves as a click chemistry reagent, containing an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, making it a versatile tool for chemical biology research. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation through the VHL E3 ligase pathway. This compound incorporates a linkable moiety suitable for AKT PROTAC applications, promoting the selective degradation of target proteins. It serves as a valuable tool in drug discovery and development, particularly in studies exploring protein turnover and cellular signaling pathways. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-PEG6-NH2 hydrochloride is a conjugate designed for E3 ligase-mediated ubiquitination, combining the cereblon ligand derived from Pomalidomide with a six-unit polyethylene glycol (PEG) linker. This compound facilitates the development of PROTAC (proteolysis-targeting chimeras) by enabling targeted protein degradation through the recruitment of E3 ligases. Its unique structure supports applications in drug discovery and targeted therapy research, particularly for modulating protein levels within cellular systems. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-C8-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for use in PROTAC technology. It features a VH032-derived VHL ligand, facilitating the targeted degradation of proteins through the ubiquitin-proteasome system. This compound is suited for applications in chemical biology and drug discovery, enabling researchers to investigate cellular pathways and protein interactions. -
Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-C10-Br is a ligand-linker conjugate targeting E3 ligases. This compound features a VHL E3 ligase linker along with MS432, which is derived from the MEK1/2 inhibitor PD0325901. It is designed for applications in chemical biology and therapeutic research, particularly in the study of protein degradation pathways and targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-PEG6-butyl iodide is a synthetic E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand connected by a six-unit PEG linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation by harnessing the ubiquitin-proteasome system. It serves as a valuable tool for researchers investigating protein regulation and degradation pathways, enhancing the development of therapeutic strategies against various diseases. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-O-Ph-PEG1-NH2 is an E3 ligase ligand-linker conjugate, designed to incorporate a VHL ligand that targets the E3 ubiquitin ligase. This compound serves as a critical component in the development of PROTAC molecules, specifically utilized in the PROTAC EED degrader-1, which targets the EED protein with a pKD of 9.02. Its application is relevant in studies of targeted protein degradation and cellular signaling pathways, making it valuable for research in cancer and other diseases influenced by protein homeostasis. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-amido-C5-acid functions as a ligand-linker conjugate targeting the VHL E3 ubiquitin ligase. This compound is designed to facilitate the development of PROTAC-based applications, effectively enabling the selective degradation of target proteins. It serves as a crucial building block in the synthesis of specialized compounds, exemplified by XY028-133. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG2-NH2 dihydrochloride is an E3 ligase ligand-linker conjugate that combines the (S,R,S)-AHPC ligand with a two-unit polyethylene glycol (PEG) linker. This compound facilitates the design and synthesis of PROTACs (Proteolysis Targeting Chimeras) by promoting targeted protein degradation. It serves as a valuable tool in drug discovery and biological research focused on elucidating cellular mechanisms and developing novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-Me-C7 ester is an E3 ligase ligand-linker conjugate designed for the synthesis of BCL-XL PROTAC degraders. This compound facilitates targeted protein degradation by linking E3 ligases with substrates, thereby enabling the selective degradation of BCL-XL. It is particularly useful in studies focused on cancer therapeutics and biochemical pathways involving protein regulation. -
E3 Ligand-Linker Conjugate
Desamino lenalidomide-acetylene-C2-NH2 TFA is an E3 ligand-linker conjugate designed to target cereblon (CRBN) for targeted protein degradation applications. This compound serves as a crucial component in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating the selective degradation of specific proteins within cells. Its unique structure enables effective recruitment of the E3 ligase, thereby expanding research potential in therapeutic strategies aimed at modulating protein levels for various biological studies. -
E3 Ligase Ligand-Linker Conjugates
Glutarimide-Isoindolinone-NH-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, facilitating the development of PROTAC (Proteolysis Targeting Chimeras) technology. This compound enables the recruitment of E3 ligases for the selective degradation of specific proteins, making it invaluable for studying protein homeostasis and therapeutic intervention. Its application extends to research in targeted protein degradation and drug discovery, enhancing the efficacy of protein-targeted approaches. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG1-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound incorporates pomalidomide, a well-characterized E3 ligase ligand, fused with a PEGylated crosslinker featuring a terminal amine. It facilitates the conjugation to carboxyl groups on target ligands, enhancing specificity and stability in biochemical assays and research involving the modulation of protein degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
E3 Ligase Ligand-Linker Conjugate 157 is designed to target E3 ligases, facilitating the formation of proteolysis-targeting chimeras (PROTACs). This conjugate plays a crucial role in the synthesis of the PROTAC degrader KT-253, enabling selective degradation of target proteins. It is a valuable tool for researchers investigating targeted protein degradation and related therapeutic applications. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-Me-C10-NH2 TFA is an E3 ligase ligand-linker conjugate designed for utilization in PROTAC (Proteolysis Targeting Chimera) technology. This compound effectively engages E3 ubiquitin ligases, facilitating the selective degradation of target proteins through ubiquitination. It serves as a valuable tool in chemical biology for the development of novel therapeutics by enabling targeted protein modulation. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG6-C2-COOH is an E3 ligase ligand-linker conjugate that features the cereblon-binding Pomalidomide compound and a six-unit polyethylene glycol (PEG) linker. This reagent is designed for use in PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation. It serves as a valuable tool for researchers exploring the modulation of E3 ligase activity and studying the implications of targeted protein degradation in various therapeutic contexts. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C1-Br is a synthetic E3 ligase ligand-linker conjugate that utilizes the (S,R,S)-AHPC-based VHL ligand along with a specialized linker for targeted protein degradation applications. This compound is essential for research involving proteolysis-targeting chimeras (PROTACs), facilitating the selective degradation of specific proteins through the ubiquitin-proteasome system. Its design enhances the engagement and modulation of E3 ligases, contributing to advancements in therapeutic strategies targeting various diseases. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-C4-Cl is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features the (S,R,S)-AHPC derivative, coupled with a 13-atom-length halogen-linked alkyl/ether-based linker. Its ability to induce the degradation of target proteins, such as GFP-HaloTag7, makes it a valuable tool for researchers investigating E3 ligase-mediated pathways and protein homeostasis in cellular models. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG5-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring Pomalidomide as the cereblon ligand. This compound effectively engages the ubiquitin-proteasome system to promote targeted protein degradation via PROTAC technology. It is suitable for applications in cancer research and therapeutic development, enabling the study of protein modulation pathways and the exploration of novel treatment strategies. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-3-methylbutanyl acetate-methanesulfonothioate-PEG3-NH2 TFA is an E3 ligase ligand-linker conjugate designed for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound features the (S,R,S)-AHPC ligand along with a three-unit PEG linker, facilitating targeted protein degradation through the ubiquitin-proteasome system. It is suitable for studies involving E3 ligase modulation and the development of novel therapeutic strategies. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG4-NH2 is a synthetic E3 ligase ligand-linker conjugate that features a Pomalidomide-derived cereblon ligand coupled with a PEG4 linker. This compound is designed to facilitate targeted protein degradation through the PROTAC (proteolysis-targeting chimera) technology. It is useful for exploring E3 ligase-mediated degradation pathways and can be applied in drug discovery and development, particularly in the context of cancer research and therapeutics. -
E3 Ligase Ligand-Linker Conjugate
(S,R,S)-AHPC-PEG1-NH2 is an E3 ligase ligand-linker conjugate that incorporates the VH032-derived VHL ligand along with a PEG1 linker. This compound is designed for use in PROTAC (PROteolysis TArgeting Chimeras) technology, facilitating targeted protein degradation in research applications. Its unique design enables the selective recruitment of E3 ligases, making it a valuable tool for studying protein regulation and degradation pathways. -
E3 Ligase Ligand-Linker Conjugate
Lenalidomide-C5-amido-Boc is a Cereblon ligand designed for the recruitment of the CRBN protein, targeting E3 ligase-mediated protein degradation pathways. This compound can be conjugated to various ligands via a spacer to produce PROTACs (proteolysis targeting chimeras), facilitating the selective degradation of specific proteins. Its application in research includes studying targeted protein elimination and elucidating protein function in various biological contexts. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-PEG3-acid is an E3 ubiquitin ligase ligand-linker conjugate designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates the recruitment of target proteins to the ubiquitin-proteasome system, enabling selective degradation of unwanted proteins in cellular contexts. It is a valuable reagent for researchers investigating targeted protein degradation and its applications in cancer therapeutics and other diseases. -
Ligand for E3 Ligase
Pomalidomide-PEG5-C2-NH2 hydrochloride is a Pomalidomide derivative functioning as a ligand for cereblon (CRBN), facilitating the recruitment of the CRBN protein. This compound is instrumental in the design of proteolysis-targeting chimeras (PROTACs) through its conjugation with other proteins via a linker. Its applications extend to targeted protein degradation studies and the exploration of CRBN-mediated pathways in cellular models. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C7-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that aids in the development of targeted protein degraders. This compound facilitates the synthesis of PROTACs (Proteolysis Targeting Chimeras), enabling selective degradation of specific proteins within cellular systems. Its unique structure supports targeted intracellular delivery and engagement with E3 ubiquitin ligases, making it a valuable reagent for research focused on protein modulation and therapeutic applications. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG3-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates the recruitment of target proteins to the E3 ligase, enhancing targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology. It serves as a valuable tool for research in protein modulation, cellular signaling pathways, and therapeutic development in oncology and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Phthalimidinoglutarimide-6-piperazine is an E3 ubiquitin ligase ligand-linker conjugate designed for the synthesis of complete Proteolysis Targeting Chimeras (PROTACs). This compound facilitates targeted protein degradation by engaging the ubiquitin-proteasome system, making it a valuable tool in drug discovery and cellular biology research. Its applications include probing E3 ligase functionality and investigating the therapeutic potential of protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Glutarimide-Isoindolinone-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound features a cereblon ligand that facilitates the recruitment of E3 ligases, promoting ubiquitination of target proteins. Its unique PEG4 linker enhances solubility and stability, making it suitable for use in PROTAC technology and related research endeavors in protein regulation and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
(S,R,S)-AHPC-C1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate designed for targeted protein degradation through PROTAC technology. This compound features the (S,R,S)-AHPC moiety, which serves as a VHL ligand, facilitating selective interactions with E3 ligases. Its application in research enables studies on protein ubiquitination and regulation, contributing to advancements in therapeutic development and cellular biology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-5-PEG4-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker. This compound is integral to the development of PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation in cellular systems. Thalidomide-5-PEG4-NH2 hydrochloride is valuable in drug discovery and therapeutic research, enabling the selective modulation of protein levels for various biological studies. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG4-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a Thalidomide-derived cereblon ligand coupled with a PEG4 linker. This compound is designed to facilitate targeted protein degradation through the PROTAC (PROteolysis TArgeting Chimeras) technology. Its unique structure allows for the selective modulation of protein levels, making it a valuable tool for research in cellular biology and drug development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-C12-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed for targeted protein degradation applications. This compound functions as a Cereblon-based degrader for KRAS G12C, facilitating the selective degradation of this oncogenic protein. It is suitable for research into innovative therapeutic strategies for KRAS-driven cancers and offers insights into the development of PROTAC technology in cancer treatment. -
E3 Ligase Ligand-Linker Conjugates
Glutarimide-Isoindolinone-NH-PEG3-COOH is an E3 ligase ligand-linker conjugate that features a cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound is designed for use in PROTAC technology, enabling targeted protein degradation through the ubiquitin-proteasome pathway. It serves as a valuable tool for research in cellular signaling, protein regulation, and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Pomalidomide-amino-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring the Pomalidomide-derived cereblon ligand. This compound incorporates a PEG4 linker, facilitating effective biomolecular interactions in PROTAC (Proteolysis Targeting Chimeras) technology. It enables targeted protein degradation, making it valuable for research applications in drug discovery and the study of protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Pomalidomide-C5-azide is a ligand-linker conjugate targeting the E3 ubiquitin ligase cereblon (CRBN). The azide moiety facilitates click chemistry, enabling the formation of covalent bonds with other bioactive molecules. This compound is suitable for research applications in protein degradation and targeted therapy development, particularly in the study of immunomodulatory effects and cellular signaling pathways. -
E3 Ligase Ligand-Linker Conjugate
E3 ligase Ligand PG-piperidine-acetaldehyde is an E3 ligase ligand-linker conjugate featuring a CRBN-based ligand. This compound is instrumental in the synthesis of proteolysis-targeting chimeras (PROTACs), facilitating targeted protein degradation. It serves as a valuable tool for research applications aimed at modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugates
1-Piperazinehexanoic acid-thalidomide functions as an E3 ligase ligand-linker conjugate, essential for the synthesis of complete JMV7048. This compound plays a critical role in the development of targeted protein degradation strategies, facilitating research into therapeutic applications in oncology and other diseases. Its structural properties enable efficient conjugation, advancing the understanding of E3 ligase modulation in biological systems.
